Quanterix Corporation

QTRX Healthcare Medical Devices

Quanterix Corporation’s revenue for fiscal 2025 (year ended December 2025) was $138.9 million, up 1.07% from fiscal 2024. In the quarter to June 2026, revenue grew 34.4%, EPS fell 35.1% and free cash flow grew 18.9%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.

2.87 0.20 −6.51%
Market cap
$145.2M
P/E
0.0×
Fwd P/E
−2.6×
Dividend yield
—
F-score
3/9
Altman Z
−0.87
Beneish M
−0.69
Dividend safety
n/a
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Piotroski F-Score
— 4 4 5 4 4 3 5 3 3
P/E ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
— (0.11) 5.21 7.16 12.17 15.10 3.18 7.33 2.44 (0.87)
P/S ratio
0.00 6.61 10.70 10.45 15.93 13.81 4.51 8.34 2.97 1.95
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z″-Score (non-manufacturers)
(9.15) 0.61 (5.98) 1.83 3.92 10.29 5.62 5.92 5.08 (1.83)
P/Operating CF
(5.78) (34.39) (49.67) (130.74) 295.64 (152.54) (107.41) (164.84) (94.80) (16.49)
Beneish M-Score
(2.59) (2.44) 1.38 (1.76) (2.18) (2.31) (2.99) (2.59) (2.35) (0.69)
P/B ratio
0.00 2.30 9.81 4.61 6.68 3.46 1.33 2.92 1.24 0.92
Price to Tangible BV
0.00 2.30 10.77 5.65 7.56 3.63 1.36 2.97 1.25 1.97
EV/Sales
0.00 3.54 9.93 8.66 14.17 10.42 1.71 6.04 1.16 1.12
EV/EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EV/Operating CF
(0.67) (3.66) (13.00) (18.77) (52.38) (24.20) (3.71) (39.24) (4.52) (2.01)
EV/FCF
(0.65) (3.48) (12.36) (13.27) (44.84) (18.80) (2.99) (32.60) (4.13) (1.95)
Quick Ratio
3.07 4.33 2.83 6.05 4.99 11.37 11.41 8.89 7.65 1.98
Current Ratio
3.22 4.53 3.28 6.69 5.52 12.14 12.17 9.80 8.66 2.84
Net Debt/EBITDA
0.91 2.75 1.22 2.67 6.61 7.75 3.43 8.38 6.26 1.16
Debt/Assets
27.60% 10.22% 11.27% 4.51% 2.83% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.76 0.14 0.19 0.06 0.04 0.00 0.00 0.00 0.00 0.00
Asset Turnover
0.79 0.35 0.47 0.48 0.39 0.29 0.23 0.28 0.33 0.34
Operating CF/Net income
0.64 0.71 0.91 0.64 0.74 0.86 0.49 0.66 0.91 0.72
Capex/Depreciation
(1.18) (2.35) (1.11) (3.00) (0.74) (2.54) (2.15) (0.50) (0.52) (0.11)
Interest Coverage
(16.73) (27.34) 685.87 66.35 (115.69) (140.25) 20.32 2.90 — —
ROE
27.11% 126.67% (58.98%) (48.07%) (18.84%) (17.17%) (24.93%) (8.01%) (11.33%) (34.25%)
ROA
(124.22%) (48.39%) (39.57%) (34.35%) (14.30%) (14.38%) (21.30%) (6.58%) (9.23%) (25.97%)
ROIC
0.00% 0.00% (462.99%) (95.71%) (61.28%) (79.41%) (339.54%) (100.39%) (80.37%) (44.21%)
Return on Tangible Assets
(108.26%) (43.67%) (71.20%) (32.67%) (16.28%) (12.92%) (26.91%) (7.85%) (11.37%) (66.48%)
Average Days of Receivables
81.30 89.34 65.88 70.16 72.61 78.53 65.78 75.81 85.37 78.76
Research and Development Expense of Revenue
96.63% 71.28% 42.00% 28.54% 23.36% 25.67% 25.41% 21.30% 22.62% 25.86%
Selling, General and Administrative Expense of Revenue
70.89% 86.07% 89.53% 92.09% 68.99% 84.04% 87.04% 72.82% 73.95% 99.36%
Intangible Assets out of Total Assets
0.00 0.00 0.05 0.14 0.09 0.04 0.02 0.01 0.01 0.38
Share Based Compensation of Revenue
5.28% 9.48% 12.98% 11.26% 11.69% 14.45% 14.58% 13.75% 14.54% 14.92%
Graham Net Nets
0.82 0.42 0.08 0.15 0.11 0.25 0.64 0.30 0.70 0.33
Graham Number
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Earnings Yield
(7.27%) (46.99%) (7.86%) (6.94%) (2.26%) (3.77%) (20.30%) (2.81%) (9.15%) (39.62%)
Free Cash Flow Yield
(85.00%) (15.37%) (7.51%) (6.25%) (1.98%) (4.02%) (12.66%) (2.22%) (9.45%) (29.44%)
Revenue per Share
8.21 6.09 1.71 2.26 2.92 3.07 2.85 3.26 3.58 3.26
Operating CF per Share
(8.28) (5.88) (1.31) (1.04) (0.79) (1.32) (1.31) (0.50) (0.92) (1.81)
Capex per Share
(0.25) (0.30) (0.07) (0.43) (0.13) (0.38) (0.31) (0.10) (0.09) (0.06)
Free Cash Flow per Share
(8.52) (6.19) (1.37) (1.48) (0.92) (1.70) (1.63) (0.60) (1.00) (1.87)
Cash per Share
13.85 21.21 2.02 4.35 6.14 11.01 9.16 8.55 7.54 2.77
Shareholders Equity per Share
6.29 17.53 1.87 5.13 6.97 12.25 9.68 9.31 8.60 6.94
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
6.29 17.53 1.87 5.13 6.97 12.25 9.68 9.31 8.60 6.94
Free Cash Flow
(18.27) (23.24) (30.22) (37.03) (27.29) (61.30) (60.22) (22.69) (38.53) (79.85)
Working Capital
24.29 69.54 41.37 112.83 179.80 411.98 350.18 343.11 321.59 137.50
Capital Expenditures
(0.53) (1.13) (1.50) (10.85) (3.93) (13.67) (11.61) (3.84) (3.37) (2.61)
Net Current Asset Value
11.60 63.34 32.95 91.37 154.69 388.38 305.87 303.49 287.10 89.22
EV/EBIT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capex to Sales
0.03 0.05 0.04 0.19 0.05 0.12 0.11 0.03 0.02 0.02
Price to Operating Income
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
0.36 0.26 0.46 0.30 0.38 0.30 0.27 0.43 0.38 1.00
Cash ROIC
(34.22%) (15.00%) (32.46%) (15.09%) (6.90%) (7.32%) (8.64%) (3.38%) (6.22%) (19.29%)
Accounts Receivable Turnover
5.69 4.81 6.07 6.41 6.15 5.40 4.93 5.51 4.78 4.47
Accounts Payable Turnover
5.05 4.22 4.54 5.49 6.07 5.72 9.22 10.84 9.05 7.21
Inventory Turnover
7.78 5.05 4.14 3.64 3.02 2.47 3.07 2.23 1.84 1.69
Average Days of Payables
94.58 100.60 94.75 70.53 64.97 73.42 23.27 38.27 46.72 66.98
Days of Inventory on Hand
56.70 101.14 110.24 127.73 141.97 176.90 102.92 198.05 220.24 270.34
Average Receivables
3.09 4.76 6.20 8.85 14.05 20.49 21.40 22.22 28.78 31.06
Average Payables
1.95 3.05 4.33 5.44 6.29 8.00 6.52 4.44 6.00 10.26
Average Inventory
1.27 2.55 4.76 8.20 12.66 18.52 19.58 21.54 29.45 43.77
Average Assets
22.23 64.45 79.70 118.78 220.50 386.29 467.55 431.07 417.55 412.65
Average Common Equity
(101.87) (24.62) 53.47 84.86 167.39 323.54 399.44 353.95 340.00 312.88

Fold the line items

Columns are period end dates